72 related articles for article (PubMed ID: 26510986)
61. Clinical implications of CYP2D6 genotyping in tamoxifen treatment for breast cancer.
Dezentjé VO; Guchelaar HJ; Nortier JW; van de Velde CJ; Gelderblom H
Clin Cancer Res; 2009 Jan; 15(1):15-21. PubMed ID: 19118028
[TBL] [Abstract][Full Text] [Related]
62. Pharmacogenetics of tamoxifen therapy in Asian populations: from genetic polymorphism to clinical outcomes.
Wang T; Zhou Y; Cao G
Eur J Clin Pharmacol; 2021 Aug; 77(8):1095-1111. PubMed ID: 33515076
[TBL] [Abstract][Full Text] [Related]
63. Genetic polymorphism of cytochrome P450 enzymes in Asian populations: focus on CYP2D6.
Kitada M
Int J Clin Pharmacol Res; 2003; 23(1):31-5. PubMed ID: 14621071
[TBL] [Abstract][Full Text] [Related]
64. Metabolism and transport of tamoxifen in relation to its effectiveness: new perspectives on an ongoing controversy.
Cronin-Fenton DP; Damkier P; Lash TL
Future Oncol; 2014 Jan; 10(1):107-22. PubMed ID: 24328412
[TBL] [Abstract][Full Text] [Related]
65. Association between genetic polymorphisms in cytochrome P450 enzymes and survivals in women with breast cancer receiving adjuvant endocrine therapy: a systematic review and meta-analysis.
Chan CWH; Li C; Xiao EJ; Li M; Phiri PGM; Yan T; Chan JYW
Expert Rev Mol Med; 2022 Jan; 24():e1. PubMed ID: 34991754
[TBL] [Abstract][Full Text] [Related]
66. Pharmacogenetics of common SNP affecting drug metabolizing enzymes: comparison of allele frequencies between European and Malaysian/Singaporean.
Bakar NS
Drug Metab Pers Ther; 2021 Mar; ():. PubMed ID: 33735954
[TBL] [Abstract][Full Text] [Related]
67. Factors Influencing Pharmacokinetics of Tamoxifen in Breast Cancer Patients: A Systematic Review of Population Pharmacokinetic Models.
Dilli Batcha JS; Raju AP; Matcha S; Raj S EA; Udupa KS; Gota V; Mallayasamy S
Biology (Basel); 2022 Dec; 12(1):. PubMed ID: 36671744
[TBL] [Abstract][Full Text] [Related]
68. CYP2D6 Genetic Polymorphisms and Phenotypes in Different Ethnicities of Malaysian Breast Cancer Patients.
Chin FW; Chan SC; Abdul Rahman S; Noor Akmal S; Rosli R
Breast J; 2016; 22(1):54-62. PubMed ID: 26510986
[TBL] [Abstract][Full Text] [Related]
69. Laboratory testing of CYP2D6 alleles in relation to tamoxifen therapy.
Lyon E; Gastier Foster J; Palomaki GE; Pratt VM; Reynolds K; Sábato MF; Scott SA; Vitazka P;
Genet Med; 2012 Dec; 14(12):990-1000. PubMed ID: 22955113
[TBL] [Abstract][Full Text] [Related]
70. The clinical effectiveness and cost-effectiveness of genotyping for CYP2D6 for the management of women with breast cancer treated with tamoxifen: a systematic review.
Fleeman N; Martin Saborido C; Payne K; Boland A; Dickson R; Dundar Y; Fernández Santander A; Howell S; Newman W; Oyee J; Walley T
Health Technol Assess; 2011 Sep; 15(33):1-102. PubMed ID: 21906462
[TBL] [Abstract][Full Text] [Related]
71. CYP2D6 polymorphisms influence tamoxifen treatment outcomes in breast cancer patients: a meta-analysis.
Zeng Z; Liu Y; Liu Z; You J; Chen Z; Wang J; Peng Q; Xie L; Li R; Li S; Qin X
Cancer Chemother Pharmacol; 2013 Aug; 72(2):287-303. PubMed ID: 23712329
[TBL] [Abstract][Full Text] [Related]
72. Impacts of Cytochrome P450 2D6 (CYP2D6) Genetic Polymorphism in Tamoxifen Therapy for Breast Cancer.
Bezerra LS; Santos-Veloso MAO; Bezerra Junior NDS; Fonseca LCD; Sales WLA
Rev Bras Ginecol Obstet; 2018 Dec; 40(12):794-799. PubMed ID: 30536272
[TBL] [Abstract][Full Text] [Related]
[Previous] [New Search]
